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Cervix and Breast cancers are the most common cancers among women worldwide and extract a large toll in developing
countries. In May 1998, supported by a grant from the NCI (US), the Tata Memorial Hospital, Mumbai, India, started a cluster-
randomized, controlled, screening-trial for cervix and breast cancer using trained primary health workers to provide health-
education, visual-inspection of cervix (with 4% acetic acid-VIA) and clinical breast examination (CBE) in the screening arm,
and only health education in the control arm. Four rounds of screening at 2-year intervals will be followed by 8 years of
monitoring for incidence and mortality from cervix and breast cancers. The methodology and interim results after three rounds
of screening are presented here. Good randomization was achieved between the screening (n 5 75360) and control arms
(n 5 76178). In the screening arm we see: High screening participation rates; Low attrition; Good compliance to diagnostic
confirmation; Significant downstaging; Excellent treatment completion rate; Improving case fatality ratios. The ever-screened
and never-screened participants in the screening arm show significant differences with reference to the variables religion,
language, age, education, occupation, income and health-seeking behavior for gynecological and breast-related complaints.
During the same period, in the control arm we see excellent participation rate for health education; Low attrition and a good
number of symptomatic referrals for both cervix and breast.
Of the estimated 470,000 new cases of cervix cancer diag-
nosed each year worldwide, 80% occur in developing coun-
tries and around 27% occur in India from where 126,000
new cases are diagnosed annually and over 71,000 deaths
because of cervix cancer are reported each year.1,2 Nearly
70% of cervix cancer patients in India present at stages III
and IV.3 Around 20% of women who develop cervix cancer
die within the first year of diagnosis and the 5-year relative
survival rate is 50%.4
Breast cancer is the most common cancer among women
worldwide and is also the leading cause of cancer deaths in
women. Breast cancer is responsible for an estimated 189,000
and 184,000 deaths in developed and developing countries
respectively thus accounting for 16% and 12% of all cancer
deaths in women. Although the age-standardized incidence
of breast cancer is generally lower in developing countries
than in developed countries (23.1 vs. 63.2 per 100,000
women), incidence rates are seen to vary widely between and
within countries. Breast cancer is already more common than
cervix cancer in a number of developing countries.5 Data
from developing countries suggests that age-standardized
incidence rates of breast cancer are rising rapidly in low-inci-
dence regions such as Africa and Asia.6
There are no organized screening programmes for cervix
and breast cancers in India. Cervix Cytology and Mammog-
raphy based screening programmes are difficult to organize
in India because of issues related to absence of trained man-
power, infrastructure, logistics, quality assurance, frequency
of screening and costs involved. Simple tests like visual
inspection of the cervix after application of 4–5% acetic acid
(VIA) and Clinical Breast Examination (CBE) have generated
considerable interest in several developing countries. VIA
has been shown to have a sensitivity ranging from 67% to
90%.7–11 Much of what we know about the benefit of the
CBE is derived from indirect evidence. The sensitivity of CBE
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in picking up breast cancers in women who have not had
much screening has been found to be much better than in
those that have had regular screening.12–16 Both VIA and
CBE are inexpensive, do not require hi-tech equipment, and
can be performed at the grass-root level by primary health
workers.17,18 Screening for cervix and breast cancers by VIA
and CBE rather than Cytology and Mammography may
therefore be a more appropriate strategy for resource poor
settings.
The undisputable proof of the efficacy of screening tests
for cervix and breast cancers would be their ability to reduce
the cervix cancer incidence and mortality and breast cancer
deaths when implemented in a program setting. Whether a
screening program using VIA and CBE will be followed by a
reduction in disease burden and mortality, and the cost effec-
tiveness of this approach based on real program information
remains to be established.
To determine the efficacy and cost-effectiveness of well
planned health education programs along with screening for cer-
vix and breast cancers using VIA and CBE, provided by trained
primary health workers, in reducing the incidence of cervix can-
cer and mortality because of cervix and breast cancers, a Clus-
ter-Randomized, Controlled, Trial was initiated in May 1998, by
investigators from the Tata Memorial Hospital, in a low socioe-
conomic, previously unscreened population, in Mumbai, India.
We present here for the first time the methodology, baseline in-
formation and the interim results after three screening rounds.
At this stage of the trial the length and lead-time biases would
affect the survival (case fatality). Both VIA and CBE being clini-
cal examination tests, the over-diagnosis bias if any would be
minimal [CBE unlike Mammography does not detect nonpalp-
able ductal carcinoma-in-situ. VIA does not detect HPV infec-
tions that are unlikely to progress to CIN, which would be oth-
erwise detected by most HPV screening tests and to some extent
by conventional cytology]. Findings of this stage of the trial will
be as valuable, as that after the completion of four screens and
the following four monitoring rounds, for planning appropriate
low cost strategies for cervix and breast cancer screening in
resource constrained populations.
The trial when completed is expected to provide valuable
information on the utility of VIA and CBE as cost effective
tools for reducing cervix and breast cancer mortality in
resource constrained settings.
Material and Methods
Design
This is a cluster randomized, controlled, trial that compares the
efficacy of health education, VIA and CBE, performed by
trained primary health workers, in reducing the incidence of cer-
vix cancer and mortality due to cervix and breast cancers among
women aged 35–64, living in the slums of Mumbai, India.
Twenty slum clusters were selected by single stage, simple
random sampling technique. These 20 clusters were then ran-
domly assigned to the screening and control (health educa-
tion) arms. We have therefore 10 clusters in the screening
arm and 10 clusters in the control.
The complete trial will include four rounds of health edu-
cation, VIA and CBE at 24-month intervals, followed by 8
years of active monitoring for cervix cancer incidence and
cervix and breast cancer mortality in the screening arm and
one round of health education at entry, followed by active
monitoring for self-reported cases and deaths due to breast
and cervix cancers in the control arm. The schema of the
trial is presented in Figure 1.
Incidence and mortality is monitored by:
a. Door-to-door survey by trained social workers
b. Data matching with the ‘‘Mumbai Municipal Death
Records’’
c. Data matching with the population-based ‘‘Mumbai
Cancer Registry’’.
Sample size
We have recruited 75,360 and 76,178 eligible women in the
screening and control arms respectively. After adjusting for
intracluster correlation (intracluster correlation and design
effect is 0.000085477 and 1.647 for cervix cancer variables
and 0.00013758 and 2.0408 for breast cancer variables), with
an alpha 0.05, the trial has 80% power to detect a 25% reduc-
tion in the cervix cancer incidence and a 40% reduction in
the cervix cancer mortality. The trial also has 80% power to
detect a 25% reduction in breast cancer mortality.
Training
Women with 10th grade education having good communica-
tion skills and preferably living in the selected clusters were
recruited and trained for 4 weeks, to perform a speculum
Figure 1. Screening trial schema.
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examination of the cervix and identify VIA positive cases fol-
lowing application of 4% acetic acid and using halogen lamp
illumination (the IARC manual for VIA was used for this
training).19 The same women were also trained to perform
CBE using a modified version of the ‘‘Canadian National
Breast Screening Study Protocol’’. Women with a graduate
degree in Medical Social Work were recruited and trained for
4 weeks, for delivering a standard health education program
for breast and cervix cancer, for conducting household sur-
veys, introducing the consent forms, pre- and post-screening
counseling and for follow-up communication. The primary
health workers and the medical social workers are given
1-week annual refresher training.
Recruitment and informed consent
The trial is approved by the Scientific and Human Ethics
Committees of the Tata Memorial Hospital. Technical and fi-
nancial reports are submitted annually to these committees
and the sponsor (National Cancer Institute, Bethesda, MD).
The Tata Memorial Hospital has an internal data monitoring
committee that monitors the trial, besides, there is an exter-
nal data safety and monitoring board that meets at least once
a year to review the trial.
Community rapport was first developed, followed by a
baseline household survey for the enlistment and a brief sen-
sitization of eligible women. Group health education pro-
grams using standard audio-visual kits were carried out next,
in both the screening and control arms. In the screening arm
the women were invited to participate in the cervix cancer
screening (VIA) and breast cancer screening (CBE) program.
Inclusion criteria
Women between the ages of 35 and 64 years, living in the
selected clusters for more than 1 year, were included in the
trial. Women who had previous history of cervix and breast
cancer (as evidenced by documented proof of histological di-
agnosis) were excluded from the trial.
Informed consent was taken after counseling by a medical
social worker and a signature (or left hand thumb impression
for illiterate women) was obtained on the consent letter that
is printed in the local language. Another woman from the
same community was invited to witness the procedure of
informed consent and was then requested to sign on the con-
sent form as a witness. All participating women received
identity cards. Trained primary health workers then per-
formed the VIA test and CBE. VIA and/or CBE positive
women were referred to the ‘‘Preventive Oncology Clinic’’ at
the Tata Memorial Hospital. A trained medical officer
(expert) blinded to the primary health workers findings,
rescreened (using the same VIA and CBE screening techni-
ques and criteria) 5% of all the screened women, selected by
simple random sampling, as part of a quality assurance pro-
gram. At the Tata Memorial Hospital, the VIA positive refer-
rals underwent colposcopy, conventional cytology and biop-
sies (in cases of positive colposcopic findings). Histologically
confirmed CIN II and above lesions and invasive cancers
were treated as per the existing treatment protocols at the
Tata Memorial Hospital. The CBE positive referrals under-
went a CBE by a surgeon specialized in the management of
breast cancer, mammography, sonography, core needle bi-
opsy or a simple excision biopsy of the lump. Histologically
confirmed cases of breast cancer were treated as per the
existing treatment protocols at the Tata Memorial Hospital.
The same procedures of community rapport building,
baseline survey and health education were followed in the
control arm. The eligible women from the control arm, how-
ever, were not invited for screening. These women were pro-
vided an identity card and information about the availability
of screening and treatment services for cervix and breast can-
cers at the Tata Memorial Hospital. Women from the control
arm who approached the Preventive Oncology Clinic at the
Tata Memorial Hospital, through symptomatic referral, seek-
ing screening or treatment for cervix or breast cancers, were
offered the same diagnostic and treatment services as that
received by women from the screening arm.
Data recording, management and analysis
Sociodemographic and risk factor information was manually
recorded by medical social workers prior to the screening.
The primary health worker records the clinical findings dur-
ing screening. Referred women have medical case history
sheets, investigation and treatment procedures recorded in
the hospital files. All the above information is transferred to
an electronic database. Data analysis is carried out in
STATAtm 8.2. The ‘‘Intracluster Correlation’’ and ‘‘Design
Effect’’ was calculated using MLWIN software. Analysis is on
intention-to-treat basis.
Results
The trial began recruiting in May 1998. Three rounds of
screening were completed in May 2005.
Socio-demographic characteristics
At the baseline, a comparison of the important socio-demo-
graphic variables showed a good equivalence of the subjects
in the screening and control arms. In both arms, the women
had a mean age of 45 years, mean age at menarche was 14
years, 54% were pre-menopausal, 2% peri-menopausal and
44% post-menopausal. Mean age at menopause for the post-
menopausal women was 43 years. The women were mostly
married (83%), mean age at marriage was 18 years. The
women had on an average four children, the mean age at
first childbirth was 21 years, and around 10% had consulted
a health care provider previously for gynecological com-
plaints. Over 98% had breastfed their children, less than 1%
had a family history of breast cancer and a little over 1% had
consulted a health care provider previously for breast-related
symptoms. In both arms, around 35% of the women had no
formal schooling, around 89–92% were homemakers, around
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45–47% lived below the poverty line and were mostly Hindus
(78–79%) (Table 1).
Participation, compliance, downstaging and mortality
reduction
Significant differences were seen between the ever-screened
and the never-screened participants in the screening arm,
with reference to important variables like age (p < 0.001),
education (p < 0.001), occupation (p ¼ 0.002), income (p <
0.001), language (p < 0.001), previous history of gynecologic
consultation (p < 0.001), previous history of consultation for
breast-related complaints (p ¼ 0.004) and family history of
breast cancer (p ¼ 0.057) (Table 2).
Cervix cancer screening
Out of 75,360 eligible women listed in the screening arm
51,145 (67.87%), 41,354 (57.84%) and 36,643 (54.26%)
women participated in the first, second and third screening
rounds for cervix cancer.
The screening positivity rates for VIA were 0.89%, 1.11%
and 0.95% during the first, second and third rounds. Compli-
ance rates for diagnostic confirmation following a positive
VIA test were 75.15%, 78.51% and 83.49% during the first,
second and third rounds of screening. (Table 3). Cohen’s
kappa for the agreement rates for VIA between the expert
and the primary health workers was 0.893.Histologically con-
firmed cases of cervix cancer were 20, 12 and 17 (around
0.03%, 0.02% and 0.03% of the eligible women) during the
first, second and third rounds of screening. Interval cervix
cancers between rounds one-two and two-three were 4 and
22 cases (Table 3). HSIL and LSIL cases were 18 and 62 in
the first round, 8 and 49 in the second round, and 18 and 24
in the third round. The mean age at detection for the screen-
ing detected cervix cancer cases was 47.41 years. The mean
age at diagnosis for interval cervix cancers was 50 years. Till
the time of completion of three rounds of screening 18
deaths out of the total 85 cervix cancer cases were recorded
(case fatality rate 21.18%).
In the control arm, we had an unusually high participa-
tion rate of 90.88% for the health education at entry. Even
during the second and third rounds, that had only door-to-
door surveillance for cervix and breast cancer morbidity and
mortality, there was a participation rate of 86.98% and 88%.
An overall attrition of 11.18% is seen at the end of the third
round. During the corresponding period, there were a good
number of symptomatic referrals from the control arm. For
cervix we had 43 symptomatic referrals with eight histologi-
cally confirmed cases at round one, 51 symptomatic referrals
with 28 histologically confirmed cases at round two, and 48
symptomatic referrals with 14 histologically confirmed cases
at round three (Table 4). For the women in the control arm
the mean age at detection of cervix cancer was 50.34 years.
During this period 15 deaths out of the 50 reported cervix
cancer cases were recorded (case fatality 30%).
Out of the 20 cases of cervix cancer detected during the
first round of screening 16 (80%) were detected in early
stages of the disease (stages 0/I/II) and 4 (20%) were detected
in advanced stages (stages III/IV). Out of the 12 cases of cer-
vix cancer detected during the second round 10 (88.33%) of
the cases were detected in early stages and 2 (16.67%) in
advanced stages. Of the 14 interval cervix cancers detected
between rounds one and two, disease-staging information
was unavailable for two cases, seven (58.33%) were diagnosed
in early stages and five (41.67%) were diagnosed in advanced
stages. All 17 cases of cervix cancer detected during the third
round were detected in early stages (100%). Of the 22 inter-
val cervix cancers detected between rounds two and three,
staging information was unavailable for 2 cases, 12 (60%)
were diagnosed in early stages and 8 (40%) were diagnosed
in advanced stages (Table 5).
In the control arm (during the period corresponding to
the first round of screening in the screening arm) eight cases
of cervix cancer were diagnosed, staging information was
unavailable for one case, one (14.29%) was diagnosed in early
stages and six (85.71%) were diagnosed in advanced stages of
the disease. During the second round 28 cases of cervix can-
cers were diagnosed, staging information was unavailable for
4 cases, 9 (37.50%) were diagnosed in early stages and 15
(62.50%) in advanced stages of the disease. During the third
round 14 cases of cervix cancers were diagnosed, staging in-
formation was unavailable for two cases, four (33.33%) were
diagnosed in early stages and eight (66.67%) in advanced
stages of the disease (Table 6).
Breast cancer screening
Out of 75,360 eligible women listed in the screening arm
69,227 (90.88%), 62,755 (86.98%) and 59,543 (88.00%)
women participated in the first, second and third screening
rounds for breast cancer. The screening positivity rates for
CBE were 0.46%, 0.77% and 0.94% during the first, second
and third rounds. Compliance rates for diagnostic confirma-
tion following a positive CBE were 68%, 70.60% and 78.06%
during the first, second and third rounds of screening (Table
7). Histologically confirmed cases of breast cancer were 32,
24 and 25 (around 0.04%, 0.03% and 0.04%) during the first,
second and third rounds of screening. Interval cancers
between rounds one-two and two-three for breast cancer
were 27 and 17 (Table 7). The mean age at detection for the
screening detected breast cancer cases was 49.80 years. The
mean age at diagnosis for interval breast cancers was 47.07
years. Till the time of completion of three rounds of screen-
ing, 22 deaths out of the total 125 breast cancer cases were
recorded (case fatality rate 17.6%).
During the corresponding period, in the control arm,
there were a good number of symptomatic referrals for breast
cancer too, we had 18 symptomatic referrals with three histo-
logically confirmed cases at round one, 61 symptomatic refer-
rals with 39 histologically confirmed cases at round two, and
76 symptomatic referrals with 45 histologically confirmed
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Table 1. Distribution by important socio-demographic variables at entry
Variables
Screening arm (n 575360)
column %
Control arm (n 5 76178)
column %
Age Groups 35–39 30.22 30.00
40–44 23.03 22.66
45–49 18.86 18.54
50–54 12.53 12.57
55–59 08.05 08.05
60–64 07.31 08.17
Mean age (SD) 44.84 (07.86) 44.92 (08.01)
Education Literate 04.14 04.82
Illiterate 35.18 35.73
School 56.23 54.44
High School þ 04.45 05.01
Income per month <Rs. 500 47.19 45.40
Rs. 501–1000 46.59 48.93
>Rs.1000 06.22 05.67
Occupation Housewife 88.60 91.93
Service 02.81 02.58
Manual labour 06.29 04.06
Self-employed 02.30 01.43
Religion Hindu 77.89 79.02
Muslim 12.99 11.39
Others 09.12 09.59
Language Marathi 56.87 53.35
Hindi 17.15 20.06
Others 25.98 26.58
Marital status Unmarried 00.40 00.60
Married 82.59 82.62
Widowed 16.48 16.38
Divorced 00.53 00.40
Menstrual status Premenopausal 53.78 53.85
Postmenopausal 43.76 44.04
Perimenopausal 02.46 02.11
Mean age at menarche (SD) 13.79 (01.26) 13.85 (01.24)
Mean age at menopause (SD) 43.36 (04.96) 43.62 (04.87)
Mean age at marriage (SD) 17.99 (03.89) 17.85 (03.82)
Mean age at first child birth (SD) 20.82 (03.70) 20.74 (03.61)
Average number of children (SD) 3.58 (01.61) 3.56 (01.61)
Previous consultation for gynecologic complaints Yes 10.70 09.87
No 89.30 90.13
Previous consultation for breast related complaints Yes 01.21 01.06
No 98.79 98.94
Family history of breast cancer Yes 00.70 00.68
No 99.30 99.32
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cases at round three (Table 8). For the women in the control
arm the mean age at detection of breast cancer was 49.79
years. During this period 10 deaths out of the 87 reported
breast cancer cases were recorded (case fatality rate 11.49%).
Cohen’s kappa for the agreement rates for CBE between the
expert and the primary health workers was 0.849.
Out of the 32 cases of breast cancer detected during the
first round of screening disease-staging information was
unavailable for two cases, 21 (70%) were detected in early
stages (stages 0/I/II) and 9 (30%) in advanced stages of the
disease (stages III/IV). Out of the 24 cases of breast cancer
detected during the second round staging information was
unavailable for two cases, 15 (68.18%) cases were detected
in early stages and seven (31.82%) in advanced stages. Of
the 27 interval breast cancers reported between screening
rounds one and two, staging information was unavailable
for four cases, 17 (73.91%) were diagnosed in early stages
and six (29.09%) in advanced stages. Out of the 25 breast
cancer cases detected during the third screening round,
staging information was unavailable for four cases, 12
(57.14%) cases were detected in early stages and nine
(42.86%) in advanced stages. Of the 17 interval breast can-
cers reported between rounds two and three, staging infor-
mation was unavailable for three cases, 13 (92.86%) were
diagnosed in early stages and one (7.14%) in advanced stage
(Table 9). In the control arm during first round three cases
of breast cancer were diagnosed, two (67%) were diagnosed
in early stages and one (33%) in advanced stage of the dis-
ease. During the second round, 39 breast cancer cases were
diagnosed, staging information was unavailable for six cases,
18 (54.55%) were diagnosed in early stages and 15 (45.45%)
in advanced stages of the disease. During the third round,
45 breast cancer cases were diagnosed, staging information
was unavailable for six cases, 18 (46.15%) were diagnosed in
early stages and 21 (53.85%) in advanced stages of the dis-
ease (Table 10).
Discussion
Screening for cervix and breast cancers in resource poor set-
tings presented a great challenge, particularly when the popu-
lation did not perceive this as a priority. Adhering to the rig-
ors of a randomized controlled trial presented further
hardships in a population that was probably being screened
for the first time. Although some amount of information was
available through the electoral rolls and census data, we
found the information inadequate and the basic demographic
information of the selected population had to be collected on
first-hand basis.
A good equivalence of the participants in the screening
and control arms is seen. The mean age at menarche (14
years) and at menopause (43 years) is typical of women from
low-nutritional settings. Marriage is universal with an average
of four children and breastfeeding is the norm (theoretically
all the above variables are protective against breast cancers).
Table 2. Distribution of screening participants and non-participants,
in the screening arm, by important socio-demographic variables
Variables
Ever-
screened
N: 63061
(row %)
Never-
screened
N: 12299
(row %)
Age group
35–44 56.08 38.48 p < 0.001
45–59 37.58 49.16
60–64 06.34 12.36
Mean age (SD) 44.32 (07.68) 47.54 (8.24)
Religion
Hindu 78.44 75.00 p < 0.001
Muslim 12.52 15.44
Christian 03.29 03.58
Buddhist 03.58 03.08
Others 02.17 02.90
Occupation
Housewife 88.45 89.35 p ¼ 0.002
White-collar worker 02.89 02.42
Manual labour 06.38 05.82
Self employed
(small business)
02.28 02.41
Education
Literate 04.05 04.59 p < 0.001
Illiterate 33.97 41.60
School 57.43 49.92
High school 03.52 02.84
Graduates 01.03 01.05
Income
Less than Rs. 500 p.m. 47.51 45.47 p < 0.001
Rs. 501–1000 p.m. 46.27 48.28
Over Rs. 1000 p.m. 06.22 06.25
Language
Marathi 57.98 51.06 p < 0.001
Hindi 17.21 16.84
Gujarati 06.53 10.46
Others 18.28 21.64
Any previous consultation for Gynaec related complaints
Yes 04.67 42.03 p < 0.001
No 95.33 57.97
Any previous consultation for breast-related complaints
Yes 01.24 00.75 p ¼ 0.004
No 98.76 99.25
Family history of breast cancer
Yes 00.69 00.93 p ¼ 0.057
No 99.31 99.07
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The consistently high participation rates for both cervix
and breast cancer screening are very good considering that
over 35% were illiterate and were exposed to cervix and
breast cancer education and screening for the first time. VIA
screening was done at least once for 83.68%, twice for
57.68% and thrice for 30% women. CBE screening was done
at least once for 93.75%, twice for 70.35% and thrice for
39.09% women. The only other trial that compared breast
cancer screening by CBE with no screening was conducted in
Philippines and had a 91.5% participation rate in the first
round of screening. The Philippines trial that was planned
for five annual examinations however ceased after the first
round because of very low compliance with clinical follow-
up.12
Low overall attrition 10.39% (screening arm) and 11.18%
(control arm) are good for long-term retaining and follow-up
of the cohort. For VIA, which is a visual test, the screening
positivity rates have remained steady through the three
screening rounds, whereas for CBE, which is a tactile test, the
screening positivity rates increased significantly after the first
round. It is probably easier to adapt with visual learning
skills when compared with tactile learning skills. The
increased CBE positivity rates could also be partly attributed
to the emergence of masses, including some cancers, over
time. The VIA positivity rates are very low when compared
with rural studies in India but are close to the rates for urban
Mumbai.7–11 The CBE positivity rates in our trial are lower
than the Philippines trial.
The success of a screening program ultimately lies in the
number of screen positives successfully treated and the deaths
prevented, which is directly dependent on the percentage of
screen-detected cases that actually seek further diagnostic and
treatment services. In this trial the average compliance rates
for diagnostic confirmation for cervix (78.95%) and breast
(73.01%) and for treatment completion for cervix (94%) and
for breast (92%) in the screen-detected cases is very good
considering the educational and socioeconomic background
of the women screened. The mean age at detection for breast
cancer (48.5 years for the screen detected and 49.5 years for
the symptomatic referrals from the control arm) is almost 5–
7 years earlier than what is typically seen in mammography
based screening programs in richer countries.20 This despite
the presence of a number of protective factors is puzzling
Table 3. (Cervix): screening participation and diagnosis in the screening arm
Screening
round Eligible women
Screened
(% of eligible)
Screen positive
(% of eligible)
Compliance-to-
diagnosis (% of
screen 1ve)
Histologically
confirmed
(% of eligible)
One 75,360 51,145 (67.87%) 672 (0.89) 505 (75.15%) 20 (0.03%)
Interval 4
Two 71,500 (attrition 5.12%) 41,354 (57.84%) 791 (1.11%) 621 (78.51%) 12 (0.02%)
Interval 22
Three 67,530 (overall attrition 10.39%) 36,643 (54.26%) 642 (0.95%) 536 (83.49%) 17 (0.03%)
Table 4. (Cervix): participation in health education/monitoring and symptomatic referrals in the control arm
Health education/
monitoring round Eligible women
Compliance to health
education/monitoring
(% of eligible)
Symptomatic
referrals
Histologically
confirmed
(% of eligible)
One 76,178 69,227 (90.88%) 43 8 (0.01%)
Two 72,145 (attrition 5.29%) 62,755 (86.98%) 51 28 (0.04%)
Three 67,664 (overall attrition 11.18%) 59,543 (88.00%) 48 14 (0.02%)
Table 5. Staging at diagnosis (cervix-screening arm)
Screening round
Early stage
(0 1 I 1 II)
Late stage
(III 1 IV)
Staging
not
available Total
One 16 (80.00%) 4 (20.00%) 0 20
Interval cancers 7 (58.33%) 5 (41.67%) 2 14
Two 10 (88.33%) 2 (16.67%) 0 12
Interval cancers 12 (60.00%) 8 (40.00%) 2 22
Three 17 (100.00%) 0 0 17
Table 6. Staging of symptomatic referrals at diagnosis
(cervix-control arm)
HE/monitoring
rounds
Early stage
(0 1 I 1 II)
Late stage
(III 1 IV)
Staging
not
available Total
One 1 (14.29%) 6 (85.71%) 1 8
Two 9 (37.50%) 15 (62.50%) 4 28
Three 4 (33.33%) 8 (66.67%) 2 14
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and requires further study of the possibility of the presence
of other risk factors.
Significant differences are seen, between the ever-screened
and the never-screened participants in the screening arm,
with reference to the variables like age, religion, language,
income, education, occupation, family history of breast can-
cer and health seeking behavior for gynecological and breast-
related complaints. This information would be very valuable
for planning cervix and breast cancer screening programs in
other similar communities.
Using a Two-tailed ‘‘Fisher’s Exact Test’’ we can see that
the intermediate end point, i.e., significant downstaging for
cervix cancer, is seen right from the first round (p ¼ 0.008)
and remains significant through rounds two (p ¼ 0.022) and
three (p < 0.001). Downstaging for breast cancer is not evi-
dent in the first (p ¼ 1.00) and second (p ¼ 0.467) rounds but
reaches significant levels in the third round (p ¼ 0.004). We
should expect this to improve as the trial progresses. The case
fatality risk ratio for cervix cancer is 0.71 and for breast cancer
is 1.53 at this stage. The difference in mortality between the
screening and control arms for cervix cancer (p ¼ 0.344) and
breast cancer (p ¼ 0.304) has not reached levels of statistical
significance. We expect to see a significant improvement in
the case fatality ratios too as the trial progresses.
The control arm that received only one round of health
education has also seen a fair number of symptomatic refer-
rals, suggesting that, for very low resource settings where
population based screening, even with VIA and CBE by pri-
mary health workers is not feasible, health education com-
bined with access to screening and treatment services, may
be a simple and feasible strategy for reduction in cervix and
breast cancer mortality.
The excellent agreement between expert and the primary
health workers is a real achievement for resource poor set-
tings where we expect that a vast majority of the population
would have to depend on primary health workers for their
routine health care needs.
On the basis of the findings of the interim analysis we
conclude that this trial, that has been planned for four
screening rounds and monitoring for another 8 years there-
after, is progressing as per plan and is expected to provide
further clues to the feasibility and efficacy of VIA and CBE
based cervix and breast cancer screening in low resource set-
tings as it progresses.
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